TY  - GEN
AU  - Capdevila, J
AU  - Hernando, J
AU  - Teule, A
AU  - Lopez, C
AU  - Garcia-Carbonero, R
AU  - Benavent, M
AU  - Custodio, A
AU  - Garcia-Alvarez, A
AU  - Cubillo, A
AU  - Alonso, V
AU  - Carmona-Bayonas, A
AU  - Alonso-Gordoa, T
AU  - Crespo, G
AU  - Jimenez-Fonseca, P
AU  - Blanco, M
AU  - Viudez, A
AU  - La Casta, A
AU  - Sevilla, I
AU  - Segura, A
AU  - Llanos, M
AU  - Landolfi, S
AU  - Nuciforo, P
AU  - Manzano, J L
AU  - García-Carbonero, Rocio
PY  - 2023
DO  - 10.1038/s41467-023-38611-5
UR  - https://hdl.handle.net/20.500.12105/23118
AB  - Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial...
LA  - eng
PB  - Nature Publishing Group
KW  - Neuroendocrine Tumors
KW  - Carcinoid Tumor
KW  - Humans
KW  - B7-H1 Antigen
KW  - Lung
TI  - Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
TY  - research article
ER  -